Vericel (VCEL) Net Cash Flow Growth (1y) (2012 - 2026)
Powered by 
Analysis
Vericel (VCEL) Net Cash Flow Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 149.49% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -104.22% |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 1,842.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,842.32% |
| Mar 31, 2026 | 272.21% |
| Dec 31, 2025 | -102.12% |
| Sep 30, 2025 | 461.03% |
| Jun 30, 2025 | -83.82% |
| Mar 31, 2025 | 66.86% |
| Dec 31, 2024 | 344.75% |
| Sep 30, 2024 | -143.19% |
| Jun 30, 2024 | -43.09% |
| Mar 31, 2024 | -249.75% |
| Dec 31, 2023 | 123.36% |
| Sep 30, 2023 | 327.94% |
| Jun 30, 2023 | 2,174.18% |
| Mar 31, 2023 | 260.75% |
| Dec 31, 2022 | -202.70% |
| Sep 30, 2022 | 6.66% |
| Jun 30, 2022 | 106.18% |
| Mar 31, 2022 | -127.30% |
| Dec 31, 2021 | 239.34% |
| Sep 30, 2021 | 123.12% |